CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive ...

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with 10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study. Safety and ...

The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...

Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...